Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yu Chen

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

Y. Chen1, G. Chen2, J. Li3, C. Huang4, Y. Li4, J. Lin1, L.Z. Chen1, J.P. Lu2, Y.Q. Wang3, C.X. Wang3, L.K. Pan5, X.F. Xia3, X. Yi3, C.B. Chen6, X.W. Zheng2, Z.Q. Guo1, J.J. Pan6

Author affiliations

  • 1 Department Of Medical Oncology, Fujian Medical University Cancer Hospital, 350000 - Fuzhou/CN
  • 2 Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 3 Geneplus-beijing Institute, Geneplus-Beijing Institute, Beijing, China, 102200 - Beijing/CN
  • 4 Department Of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Medical University, 300014 - Fuzhou/CN
  • 5 Hui Xian Medical Center, Hui Xian Medical Center, 999078 - Macao/CN
  • 6 Department Of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Medical University Cancer Hospital, 300014 - Fuzhou/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2314

Background

Immune checkpoint inhibitors (ICIs) elicits durable responses in non–small cell lung cancer (NSCLC), but only a fraction of patients responded. TP53 and ATM co-mutation may lead to genomic instability and hypermutation. However, the prevalence and utility of a TP53/ATM co-mutation as a biomarker to ICIs are not fully understood.

Methods

This was a multiple cohort pooled study, 2020 NSCLC samples from Geneplus Institute, 1031 samples from TCGA, 1567 samples from MSKCC, 853 samples from POLAR/OAK databases were statically analyzed. Next-generation sequencing assays were performed in the Geneplus Institute. Genomic, transcriptomic and clinical data were obtained from the TCGA, MSKCC, POLAR/OAK databases. Comprehensive profiling was performed to determine the prevalence of TP53/ATM co-mutation and correlation with the prognosis and the response to ICIs.

Results

TP53/ATM co-mutation sites were found to be scattered throughout the genes and we did not observe any significant difference in TP53/ATM co-mutated frequency within the histologic subtypes and driver genes. In five independent NSCLC cohorts, TP53/ATM co-mutation contributed to significantly higher tumor mutation burden (TMB) compared to both the sole mutation and both wild type groups. Furthermore, in the MSKCC-IO cohort, a TP53/ATM co-mutation was associated with better OS than sole mutation and both wild type groups, especially in pan-cancer (P=.241, NSCLC and P<.0001, Pan-cancer). Similar results were shown in the POLAR/OAK cohort, the disease control benefit rate, and progression free survival (PFS) and OS were all greater in patients with the TP53/ATM co-mutation compared with the other three groups. GSEA showed that IFN-α response, IFN-γ response, IL6/JAK/STAT3 signaling, and TNF-α signaling pathways had higher levels of activation and there was greater PD-L1 expression in the co-mutated group, compared with solely mutated and both wild type group.

Conclusions

Our findings suggest that patients with TP53/ATM co-mutation comprise a special subgroup of NSCLC patients and correlate with increasing TMB and responses to ICIs. It may have implications for potential predictive biomarker in guiding ICIs immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Jian Ji Pan.

Funding

National Natural Science Foundation of China (Grant No. U1705282).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.